The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process.
SciSparc Ltd a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced additional positive pre-clinical results in ongoing series of research studies of treatment for cocaine using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc
The results are in connection with the ongoing collaboration between the Company and Clearmind and the provisional patent application for treating cocaine addiction with Clearmind, based on SciSparc
